Paula Vera-Artazcoz

Prof. Dr. Paula Vera-Artazcoz

Hospital de Sant Pau, Barcelona, Catalonia, Spain
+2
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2010 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
LZLluís Zapata
Lluís Zapata
PVPaula Vera-Artazcoz
Paula Vera-Artazcoz
ARAntoni Roglan
Antoni Roglan
IGIgnasi Gich
Ignasi Gich
Jorge Ordonez-LlanosJorge Ordonez-Llanos
Jorge Ordonez-Llanos
ABAntoni J. Betbesé
Antoni J. Betbesé

1 July 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
ATAlfons Torrego
Alfons Torrego
VPVirginia Pajares
Virginia Pajares
CFCarmen Fernández-Arias
Carmen Fernández-Arias
PVPaula Vera-Artazcoz
Paula Vera-Artazcoz
JMJordi Mancebo
Jordi Mancebo

1 February 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
LSLluís Servia-Goixart
Lluís Servia-Goixart
Juan Carlos Lopez-DelgadoJuan Carlos Lopez-Delgado
Juan Carlos Lopez-Delgado
TGTeodoro Grau
Teodoro Grau
JCJavier Trujillano Cabello
Javier Trujillano Cabello
LBLuisa Bordeje
Luisa Bordeje
EIENPIC Study Investigators
ENPIC Study Investigators
The importance of artificial nutritional therapy is underrecognized, typically being considered an adjunctive rather than a primary therapy. We aimed to evaluate the influence of nutritional therapy on mortality in critically ill patients. This multicenter prospective observational study included adult patients needing artificial nutritional therapy for >48 h if they stayed in one of 38 participating intensive care units for ≥72 h between April and July 2018. Demographic data, comorbidities, diagnoses, nutritional status and therapy (type and details for ≤14 days), and outcomes were registered in a database. Confounders such as disease severity, patient type (e.g., medical, surgical or trauma), and type and duration of nutritional therapy were also included in a multivariate analysis, and hazard ratios (HRs) and 95% confidence intervals (95%CIs) were reported. We included 639 patients among whom 448 (70.1%) and 191 (29.9%) received enteral and parenteral nutrition, respectively. Mortality was 25.6%, with non-survivors having the following characteristics: older age; more comorbidities; higher Sequential Organ Failure Assessment (SOFA) scores (6.6 ± 3.3 vs 8.4 ± 3.7; P < 0.001); greater nutritional risk (Nutrition Risk in the Critically Ill [NUTRIC] score: 3.8 ± 2.1 vs 5.2 ± 1.7; P < 0.001); more vasopressor requirements (70.4% vs 83.5%; P=0.001); and more renal replacement therapy (12.2% vs 23.2%; P=0.001). Multivariate analysis showed that older age (HR: 1.023; 95% CI: 1.008-1.038; P=0.003), higher SOFA score (HR: 1.096; 95% CI: 1.036-1.160; P=0.001), higher NUTRIC score (HR: 1.136; 95% CI: 1.025-1.259; P=0.015), requiring parenteral nutrition after starting enteral nutrition (HR: 2.368; 95% CI: 1.168-4.798; P=0.017), and a higher mean Kcal/Kg/day intake (HR: 1.057; 95% CI: 1.015-1.101; P=0.008) were associated with mortality. By contrast, a higher mean protein intake protected against mortality (HR: 0.507; 95% CI: 0.263-0.977; P=0.042). Old age, higher organ failure scores, and greater nutritional risk appear to be associated with higher mortality. Patients who need parenteral nutrition after starting enteral nutrition may represent a high-risk subgroup for mortality due to illness severity and problems receiving appropriate nutritional therapy. Mean calorie and protein delivery also appeared to influence outcomes. ClinicaTrials.gov NCT: 03634943.

3 November 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Juan Carlos Lopez-DelgadoJuan Carlos Lopez-Delgado
Juan Carlos Lopez-Delgado
TGTeodoro Grau-Carmona
Teodoro Grau-Carmona
EMEsther Mor-Marco
Esther Mor-Marco
LBLuisa Bordeje
Luisa Bordeje
EPEsther Portugal-Rodriguez
Esther Portugal-Rodriguez
OGon behalf of the ENPIC Study Group
on behalf of the ENPIC Study Group
Background: Parenteral nutrition (PN) is needed to avoid the development of malnutrition when enteral nutrition (EN) is not possible. Our main aim was to assess the current use, complications, and nutrition delivery associated with PN administration in adult critically ill patients, especially when used early and as the initial route. We also assessed the differences between patients who received only PN and those in whom EN was initiated after PN (PN-EN). Methods: A multicenter (n = 37) prospective observational study was performed. Patient clinical characteristics, outcomes, and nutrition-related variables were recorded. Statistical differences between subgroups were analyzed accordingly. Results: From the entire population (n = 629), 186 (29.6%) patients received PN as initial nutrition therapy. Of these, 74 patients (11.7%) also received EN during their ICU stay (i.e., PN-EN subgroup). PN was administered early (<48 h) in the majority of patients (75.3%; n = 140) and the mean caloric (19.94 ± 6.72 Kcal/kg/day) and protein (1.01 ± 0.41 g/kg/day) delivery was similar to other contemporary studies. PN showed similar nutritional delivery when compared with the enteral route. No significant complications were associated with the use of PN. Thirty-two patients (43.3%) presented with EN-related complications in the PN-EN subgroup but received a higher mean protein delivery (0.95 ± 0.43 vs 1.17 ± 0.36 g/kg/day; p = 0.03) compared with PN alone. Once adjusted for confounding factors, patients who received PN alone had a lower mean protein intake (hazard ratio (HR): 0.29; 95% confidence interval (CI): 0.18–0.47; p = 0.001), shorter ICU stay (HR: 0.96; 95% CI: 0.91–0.99; p = 0.008), and fewer days on mechanical ventilation (HR: 0.85; 95% CI: 0.81–0.89; p = 0.001) compared with the PN-EN subgroup. Conclusion: The parenteral route may be safe, even when administered early, and may provide adequate nutrition delivery. Additional EN, when possible, may optimize protein requirements, especially in more severe patients who received initial PN and are expected to have longer ICU stays. NCT Registry: 03634943.

1 December 2012 in Medicina Intensiva (English Edition)
Verified
Journal Article
Closed access
PVPaula Vera-Artazcoz
Paula Vera-Artazcoz
LZL. Zapata
L. Zapata
IGIgnasi Gich
Ignasi Gich
JMJ. Mancebo
J. Mancebo
ABA.J. Betbesé
A.J. Betbesé

1 August 2021 in Medicina Intensiva (English Edition)
Verified
Journal Article
Closed access
FLF. Álvarez Lerma
F. Álvarez Lerma
CZC. Beato Zambrano
C. Beato Zambrano
FVF. Gordo Vidal
F. Gordo Vidal
CSC. Ruano Suarez
C. Ruano Suarez
TPT. Aldabó Pallás
T. Aldabó Pallás
EPEnrique Alemparte Pardavila
Enrique Alemparte Pardavila